Get the Stockscreener App
8.35
1.76%
-0.15
Prothena Corp Plc stock is traded at $8.35, with a volume of 670.25K.
It is down -1.76% in the last 24 hours and up +1.33% over the past month.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
See More
Previous Close:
$8.50
Open:
$8.58
24h Volume:
670.25K
Relative Volume:
1.08
Market Cap:
$428.66M
Revenue:
$57.94M
Net Income/Loss:
$-151.18M
P/E Ratio:
-2.9698
EPS:
-2.8116
Net Cash Flow:
$-86.56M
1W Performance:
-5.54%
1M Performance:
+1.33%
6M Performance:
-20.63%
1Y Performance:
-17.24%
1-Day Range:
$8.24
$8.62
1-Week Range:
$8.19
$8.81
52-Week Range:
$7.73
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
Name
Prothena Corp Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
8.35 | 428.66M | 57.94M | -151.18M | -86.56M | -2.8116 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corp Plc Stock (PRTA) Latest News
Form 4 PROTHENA CORP PUBLIC LTD CO For: 11 October By Investing.com - Investing.com Nigeria
Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October By Investing.com - Investing.com Canada
Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October By Investing.com - Investing.com India
Form 4 PROTHENA CORP PUBLIC LTD CO For: 10 October By Investing.com - Investing.com South Africa
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Prothena Director William P. Scully Acquires 100,000 Shares at $8.57 Each - Kalkine Media
Insider Stock Purchases: October 06, 2026 - Quiver Quantitative
A development chief is leaving Prothena (PRTA) to join one of its strategic partners. - stocktitan.net
Prothena Corporation Public Limited Company Announces Resignation of Chad J. Swanson, Ph.D. as Chief Development Officer, Effective October 9, 2026 - marketscreener.com
Form 4 PROTHENA CORP PUBLIC LTD CO For: 1 October By Investing.com - Investing.com Canada
Form 4 PROTHENA CORP PUBLIC LTD CO For: 29 September By Investing.com - Investing.com Nigeria
Form 4 PROTHENA CORP PUBLIC LTD CO For: 29 September By Investing.com - Investing.com Canada
Form 4 PROTHENA CORP PUBLIC LTD CO For: 29 September By Investing.com - Investing.com UK
Form 4 PROTHENA CORP PUBLIC LTD CO For: 27 September - Investing.com India
Insider Stock Purchases: September 24, 2026 - Quiver Quantitative
Prothena Director William P. Scully Acquires 100,000 Shares at Average Price of $8.43 - kalkinemedia.com
Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing - Yahoo Finance
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
A biotech company's leaders will speak live in New York Sept. 16 - Stock Titan
Prothena stock holds near USD 9.60 after market cap update - AD HOC NEWS
Prothena Director William P. Scully Acquires 27,000 Shares in Open Market - kalkinemedia.com
Responsive Playbooks and the PRTA Inflection - Stock Traders Daily
Sarissa Capital Management and Alexander J. Denner Hold 25.7 Million Shares in Amarin Corporation (NASDAQ: AMRN) - kalkinemedia.com
Prothena Corporation plc (PRTA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Prothena Stock Price Forecast. Should You Buy PRTA? - StockInvest.us
Prothena Corporation plc (PRTA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Prothena Corporation plc (PRTA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock - MarketBeat
Prothena (NASDAQ: PRTA) insider lifts direct stake to 800,000 shares - stocktitan.net
Trustee controls a tenth of Prothena (PRTA) stock via trusts - Stock Titan
Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Prothena (PRTA) Holds Steady Near $8.88 as Shares Sit Between Key Support and ResistancePositive Gamma - vinanet.vn
Prothena (PRTA) 10% holder logs 963K-share gifts - Stock Titan
Precision Trading with Prothena Corporation Plc (PRTA) Risk Zones - Stock Traders Daily
HC Wainwright Issues Positive Estimate for Prothena Earnings - MarketBeat
Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise - Sahm
Prothena Corporation PLC (PRTA) Stock News Today - TradingKey
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - tradingview.com
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - Yahoo Finance
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com
Prothena: Q2 Earnings Snapshot - marketscreener.com
Prothena: Q2 Earnings Snapshot - Yahoo Finance
Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone - Stock Titan
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - marketscreener.com
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - Yahoo Finance
FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4% - stocktitan.net
Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena Corp Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corp Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 10% Owner |
Oct 14 '26 |
Buy |
8.46 |
10,000 |
84,569 |
1,037,000 |
| SCULLY WILLIAM P | 10% Owner |
Oct 08 '26 |
Buy |
8.57 |
90,000 |
770,904 |
529,000 |
| SCULLY WILLIAM P | 10% Owner |
Oct 07 '26 |
Buy |
8.40 |
125,000 |
1,050,150 |
439,000 |
| SCULLY WILLIAM P | 10% Owner |
Oct 02 '26 |
Buy |
8.57 |
100,000 |
857,240 |
314,000 |
| SCULLY WILLIAM P | 10% Owner |
Sep 29 '26 |
Buy |
8.68 |
162,000 |
1,405,674 |
214,000 |
| SCULLY WILLIAM P | 10% Owner |
Sep 28 '26 |
Buy |
8.60 |
103,500 |
889,872 |
187,000 |
| SCULLY WILLIAM P | 10% Owner |
Sep 18 '26 |
Buy |
8.43 |
100,000 |
843,460 |
927,000 |
| SCULLY WILLIAM P | 10% Owner |
Sep 02 '26 |
Buy |
9.47 |
27,000 |
255,739 |
827,000 |
| SCULLY WILLIAM P | 10% Owner |
Aug 20 '26 |
Buy |
8.79 |
50,000 |
439,430 |
800,000 |
| SCULLY WILLIAM P | 10% Owner |
Aug 07 '26 |
Buy |
8.62 |
3,500 |
30,167 |
83,500 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):